Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses.

Eid SG, Mangan NE, Hertzog PJ, Mak J.

Clin Transl Immunology. 2015 Oct 9;4(10):e43. doi: 10.1038/cti.2015.23. eCollection 2015 Oct. Review.

2.

A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.

Bunge KE, Dezzutti CS, Rohan LC, Hendrix CW, Marzinke MA, Richardson-Harman N, Moncla BJ, Devlin B, Meyn LA, Spiegel HM, Hillier SL.

J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):498-505. doi: 10.1097/QAI.0000000000000897.

PMID:
26565716
3.

Development of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studies.

Jacot TA, Nelson A, Thurman A, Kashuba AD, Archer DF, Doncel GF.

PLoS One. 2014 Dec 9;9(12):e114368. doi: 10.1371/journal.pone.0114368. eCollection 2014.

4.

Abasic phosphorothioate oligomers inhibit HIV-1 reverse transcription and block virus transmission across polarized ectocervical organ cultures.

Fraietta JA, Mueller YM, Lozenski KL, Ratner D, Boesteanu AC, Hancock AS, Lackman-Smith C, Zentner IJ, Chaiken IM, Chung S, LeGrice SF, Snyder BA, Mankowski MK, Jones NM, Hope JL, Gupta P, Anderson SH, Wigdahl B, Katsikis PD.

Antimicrob Agents Chemother. 2014 Dec;58(12):7056-71. doi: 10.1128/AAC.02991-14. Epub 2014 Sep 15.

5.

Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation.

Dezzutti CS, Russo J, Wang L, Abebe KZ, Li J, Friend DR, McGowan IM, Rohan LC.

PLoS One. 2014 Jul 15;9(7):e102585. doi: 10.1371/journal.pone.0102585. eCollection 2014.

6.

Topical microbicides and HIV prevention in the female genital tract.

Cottrell ML, Kashuba AD.

J Clin Pharmacol. 2014 Jun;54(6):603-15. doi: 10.1002/jcph.292. Epub 2014 Mar 28. Review.

7.

Adherence in the CAPRISA 004 tenofovir gel microbicide trial.

Mansoor LE, Abdool Karim Q, Yende-Zuma N, MacQueen KM, Baxter C, Madlala BT, Grobler A, Abdool Karim SS.

AIDS Behav. 2014 May;18(5):811-9. doi: 10.1007/s10461-014-0751-x.

8.

Who will Benefit from a Wide-Scale Introduction of Vaginal Microbicides in Developing Countries?

Dimitrov DT, Masse B, Boily MC.

Stat Commun Infect Dis. 2010 Jan;2(1):1012.

9.

The implications of post-coital intravaginal cleansing for the introduction of vaginal microbicides in South Africa.

Gafos M, Pool R, Mzimela MA, Ndlovu HB, McCormack S, Elford J; MDP team.

AIDS Behav. 2014 Feb;18(2):297-310. doi: 10.1007/s10461-013-0676-9.

10.

Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS.

Gupta SK, Nutan.

HIV AIDS (Auckl). 2013 Oct 22;5:295-307. doi: 10.2147/HIV.S39164. Review.

11.

Pregnancy incidence and risk factors among women participating in vaginal microbicide trials for HIV prevention: systematic review and meta-analysis.

Musekiwa A, Muchiri E, Manda SO, Mwambi HG.

PLoS One. 2013 Oct 10;8(10):e77014. doi: 10.1371/journal.pone.0077014. eCollection 2013. Review.

12.

Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.

Gengiah TN, Moosa A, Naidoo A, Mansoor LE.

Int J Clin Pharm. 2014 Feb;36(1):70-85. doi: 10.1007/s11096-013-9861-1. Epub 2013 Oct 16. Review.

13.
14.

Polyanionic candidate microbicides accelerate the formation of semen-derived amyloid fibrils to enhance HIV-1 infection.

Tan S, Lu L, Li L, Liu J, Oksov Y, Lu H, Jiang S, Liu S.

PLoS One. 2013;8(3):e59777. doi: 10.1371/journal.pone.0059777. Epub 2013 Mar 27.

15.

Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice.

Chateau ML, Denton PW, Swanson MD, McGowan I, Garcia JV.

PLoS One. 2013;8(3):e60024. doi: 10.1371/journal.pone.0060024. Epub 2013 Mar 20.

16.

Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda.

Abaasa A, Crook A, Gafos M, Anywaine Z, Levin J, Wandiembe S, Nanoo A, Nunn A, McCormack S, Hayes R, Kamali A.

Trials. 2013 Feb 1;14:33. doi: 10.1186/1745-6215-14-33.

17.

Twice-daily application of HIV microbicides alter the vaginal microbiota.

Ravel J, Gajer P, Fu L, Mauck CK, Koenig SS, Sakamoto J, Motsinger-Reif AA, Doncel GF, Zeichner SL.

MBio. 2012 Dec 18;3(6). pii: e00370-12. doi: 10.1128/mBio.00370-12.

18.

Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis.

Obiero J, Mwethera PG, Hussey GD, Wiysonge CS.

BMC Infect Dis. 2012 Nov 6;12:289. doi: 10.1186/1471-2334-12-289. Review.

19.

The meaning of adherence when behavioral risk patterns vary: obscured use- and method-effectiveness in HIV-prevention trials.

de Bruin M, Viechtbauer W.

PLoS One. 2012;7(8):e44029. doi: 10.1371/journal.pone.0044029. Epub 2012 Aug 31.

20.

State of the science of adherence in pre-exposure prophylaxis and microbicide trials.

Muchomba FM, Gearing RE, Simoni JM, El-Bassel N.

J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):490-8. doi: 10.1097/QAI.0b013e31826f9962. Review.

Items per page

Supplemental Content

Write to the Help Desk